Related Experiment Videos

[Hyperthermic reaction in the perioperative phase in 2 children with acute lymphoblastic leukemia of B-cell type]

C Schnorr1, H Müller, T Menges

  • 1Abteilung Anaesthesiologie und Operative Intensivmedizin, Klinikum der Justus-Liebig-Universität Giessen.

Der Anaesthesist
|February 1, 1989
PubMed

Insights

Children with acute lymphoblastic beta-cell leukemia (B-ALL) may be susceptible to malignant hyperthermia during anesthesia. Early detection and dantrolene treatment are crucial for managing these reactions in pediatric leukemia patients.

Area of Science:

  • Pediatric Oncology
  • Anesthesiology
  • Pharmacology

Background:

  • Acute lymphatic leukemia (ALL) is a common childhood malignancy requiring central venous access for chemotherapy.
  • Malignant hyperthermia (MH) is a rare, life-threatening reaction to certain anesthetic agents.

Observation:

  • Two pediatric patients with acute lymphoblastic beta-cell leukemia (B-ALL) developed hyperthermia during anesthesia.
  • Symptoms included elevated temperature, increased expired CO2, acidosis, and cardiovascular changes, consistent with MH.

Findings:

  • The hyperthermic reactions responded to dantrolene sodium, a specific MH treatment.
  • One patient experienced recurrent hyperthermia upon dantrolene withdrawal, confirming the diagnosis and treatment efficacy.

Implications:

  • Children with B-ALL may have an increased susceptibility to malignant hyperthermia.
  • Close monitoring for MH symptoms during anesthesia in these patients is recommended.
  • Prompt dantrolene administration is vital for managing MH in pediatric leukemia patients.

Related Concept Videos